Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like.

Abstract: A method of applying makeup to a surface, such as the skin, the nails, hair, or the lips, is disclosed. The method includes manually depositing, using a non-magnetic cosmetic applicator, at least a first cosmetic composition in the fluid state on the surface, the first composition containing magnetic particles that are movable under the effect of a magnetic field; and manually exposing at least part of the first composition to a magnetic device producing a magnetic field, the magnetic device located above the first composition so as to orientate and/or displace at least a fraction of the magnetic particles so as to form at least one pattern according to magnetic field lines of the magnetic field without making contact with the first composition.

Abstract: The present invention relates to a method of applying makeup to keratinous substances, in particular the skin, the lips, the nails, or hair, the method comprising the following steps: depositing at least one cosmetic composition on the surface to be made up, the cosmetic composition comprising: bodies that present non-zero magnetic susceptibility and that are movable under the effect of a magnetic field; and at least one interferential pigment; and exposing at least part of the composition to a magnetic field, so as to modify the orientation and/or displace at least some of the magnetic bodies.

Abstract: A method for stabilizing conjugates between macromolecule and nanoparticle by forming a thin reinforcement layer over the surface of a nanoparticle after macromolecule chains have attached to the surface of the nanoparticle. The stabilized conjugates can be used in a wide range of applications such as in vitro diagnostics, in vivo imaging and therapeutics, which need to be conducted under various severe or harsh conditions.

Abstract: The present invention provides a banding composition for hard capsules using hydroxypropylmethyl cellulose (HPMC) as a base comprising (1) low viscosity HPMC; (2) a component selected from the group consisting of methanol, ethanol, isopropanol, 1-propanol, acetone and/or ethyl acetate; (3) a surfactant; and (4) water; and a method for banding hard capsules using hydroxypropylmethyl cellulose as a base by using the banding composition described.

Abstract: According to an aspect of the present invention, various medical devices, including implantable or insertable medical devices, are provided, which comprise at least one particle-containing region whose surface is at least partially coated with a diamond-like coating.

Abstract: The present disclosure is directed to compounds of the structure (X): CoreL-NHE)n??(X) wherein: n is 2 or 3; NHE has the structure wherein: R1 is H or —SO2—NR7R8—; R2 is selected from H, —NR7(CO)R8, —SO2—NR7R8— and —NR7R8; R3 is hydrogen; R7 is hydrogen; R8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(?O)—, —NHC(?O)NH— and —NHSO2—; and Y is selected from the group consisting of a bond, optionally substituted C1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH2)1-6O(CH2)1-6—, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.

Abstract: The present invention relates to a deodorant composition containing (a) a polyphenol compound or a plant extract containing a polyphenol compound, (b) a basic substance, and (c) a metal salt. The deodorant composition of the present invention is capable of providing a deodorizing effect in a short period of time when it is applied to a malodor source, is capable of providing an excellent deodorizing activity and is also excellent in the store stability.

Abstract: A pharmaceutical dosage form which comprises two or more different hyoscyamine formulations, at least one of the formulations being an immediate release hyoscyamine formulation and at least one other one being a controlled release hyoscyamine formulation. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: The present invention relates to shelf stable and/or less corrosive peroxycarboxylic acid antimicrobial compositions, including ready-to-use compositions. Shelf stable compositions can include defined ratios of hydrogen peroxide to peroxycarboxylic acid and/or hydrogen peroxide to protonated carboxylic acid, but need not include strong acid. Reduced corrosion compositions can include carboxylic acid and corrosion inhibitor at acid pH. Compositions of the invention can have advantageous activity against spores.

Abstract: Gel nanoparticles for encapsulating and delivering a pharmaceutical compound to a patient. The nanoparticles are formed from N-trimethyl chitosan and polysialic acid, preferably in the presence of sodium tripolyphosphate. A ratio of polysialic acid to N-trimethyl chitosan of about 0.5 to 1 produces nanoparticles having diameter of about 100 nm (plus or minus 25 nm) and a zeta potential above 30 milivolts that can stability contain a pharmaceutical compound, such as methotrexate, for delivery to a patient.

Abstract: Cosmetic bases consisting of alkylene oxide derivatives represented by the general formula (I): Z—{O(AO)l(EO)m—(BO)nH}a(I) wherein Z is a residue derived from a compound having three to nine hydroxyl groups by the removal of the hydroxyl groups; a is 3 to 9; AO is C3-4 oxyalkylone; EO is oxyethylene; l and m represent the average numbers of added C3-4 oxyalkylene molecules and oxyalkylene molecules respectively and satisfy the relationships: 1?1?50 and l?m?50 respectively; the AO/EO weight ratio is 1/5 to 5/1 and AO's and EO's may be added at random or in block; BO is oxyalkylene having 4 carbon atoms; and n represents the average number of added BO molecules and satisfies the relationship: 0.5?n?5.

Abstract: The present invention is an enteric coated granule having controlled dissolution in water even at a small coating amount; and a preparation method thereof.

Abstract: The present invention relates to a method for providing a fiber-containing pectin product from a plant material. The method comprises the steps of: (i) providing a plant material comprising pectin, where said pectin is having a degree of esterification of 55% or less, (ii) adding an acidic aqueous solution to the pectin containing plant material obtained in step (i) and providing a suspension of the plant material, where the suspended plant material provides an in situ system by swelling the plant material under conditions where the pectin is kept within the plant material, and (iii) obtaining the fiber-containing pectin product from the suspension provided in step (ii), wherein the plant material is substantially depleted from divalent cations.

Abstract: The present invention discloses a process of preparing jambu extract that results in a jambu extract free from chlorophyll and derivatives of this compound. It is a method for isolating the components of interest in a simplified way, with quite high process yield, higher than 85%. The present invention further relates to the use of this extract in preparing cosmetic compositions, the cosmetic compositions comprising said extract, and to cosmetic products comprising said cosmetic compositions.

Abstract: The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure

Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

Abstract: The present disclosure is directed to compounds of the structure (X): wherein: n is 2 or 3; NHE has the structure wherein: R1 is H or —SO2—NR7R8—; R2 is selected from H, —NR7(CO)R8, —SO2—NR7R8— and —NR7R8; R3 is hydrogen; R7 is hydrogen; R8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(?O)—, —NHC(?O)NH— and —NHSO2—; and Y is selected from the group consisting of a bond, optionally substituted C1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH2)1-6O(CH2)1-6—, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.

Abstract: A method of UV curing and corresponding resulting non-polymeric cross-linked gel are provided. The cross-linked gel can be combined with a medical device structure. The cross-linked gel can provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The cross-linked gel is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel derived from at least one fatty acid compound. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent. The curing method can vary the application of UV light in both intensity and duration to achieve a desired amount of cross-linking forming the gel.